Insili Intelligence (03696) and Prorui announce a strategic alliance to advance AI-driven drug development

According to the Zhitong Finance App, Insilicon Intelligence (03696) issued an announcement. Insilicon Smart and Borui Pharmaceutical Co., Ltd. (Baorui; Taiwan Stock Exchange: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, announced a multi-faceted strategic alliance. The alliance will lay the foundation for a broad, multi-faceted cooperation framework. The details of the cooperation are subject to further discussion and the signing of a final agreement between the two sides. If fully implemented, the potential value of the proposed collaboration is expected to exceed $2.5 billion.

The proposed cooperation under the alliance will be agreed upon by Insilis Intelligence and Borui through subsequent negotiations and the signing of a final agreement. The aim is to integrate the technical advantages of InsiliSmart's own Pharma.ai platform in target discovery, generative chemistry, and molecular optimization, as well as Pray's expertise in global drug development, manufacturing, quality management, and commercialization. By opening up AI-enabled R&D systems and automation-driven development, manufacturing, and quality execution processes, Insilis and Borui aim to jointly develop a new generation of drug innovation models, connecting the design and development of novel molecules with the capabilities needed to deliver drugs to patients who do not meet medical needs.